Zymeworks

November 04, 2019

SITC 2019 preview – Pieris joins the quest for a better Herceptin

Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.

September 10, 2019

Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus

Away from the main small-molecule focus of this year’s Esmo meeting, Keytruda flies the flag for immuno-oncology, including in a little-noticed mesothelioma study.

September 01, 2017

Macrogenics and J&J fallout could spell double trouble

July 05, 2017

Biotech floats come back with a vengeance

The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.

July 14, 2016

Biotech venture funding falls from 2015 peak

April 13, 2016

Zymeworks

SITC 2019 preview – Pieris joins the quest for a better Herceptin

Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus

Macrogenics and J&J fallout could spell double trouble

Biotech floats come back with a vengeance

Biotech venture funding falls from 2015 peak

First-quarter venture financing: the retrenchment begins

Latest Reports

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

Editor's Picks

Shock revelation sees Biogen erase its aducanumab losses

Vertex’s double cystic fibrosis surprise

Bristol might play a role in front-line lung cancer after all

Bloated on arrival? Biotech's weightiest new issues

Uncovering biopharma’s hidden treasures